Search Team

Search by Last Name
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Background

Geoff Biegler is a Principal in Fish’s Southern California office with an expansive litigation practice that spans all areas of intellectual property and complex commercial litigation, with a particular focus on pharmaceutical and life sciences litigation. He has extensive experience litigating both Hatch-Waxman cases and competitor pharmaceutical and biotechnology cases for products including ODEFSEY®, DESCOVY®, VEMLIDY®, SOVALDI®, HARVONI®, and EPCLUSA® (Gilead), YESCARTA® (Kite), XELODA® (Genentech/Roche), AMRIX® (Cephalon), BRCA1/BRCA2 genetic testing (Myriad Genetics), and CRISPR-Cas9 technology.

Mr. Biegler has successfully managed and tried matters through all phases of litigation, mediation, and arbitration in a variety of forums, spanning from the District of Delaware to the Southern District of California, including the U.S. International Trade Commission. In addition to his experience in U.S. jurisdictions, Mr. Biegler also has significant experience managing and harmonizing patent disputes that include fronts on multiple, international jurisdictions.

In the courtroom, Mr. Biegler has conducted numerous witness examinations at trial and argued a variety of dispositive and non-dispositive motions, including Markman hearings and preliminary injunctions. Mr. Biegler has also handled due diligence efforts, pre-suit investigations, managed complex discovery, and assisted his clients in managing post-grant proceedings before the Patent Trial and Appeals Board.

Mr. Biegler teaches life sciences trial and patent practice courses and speaks on patent litigation topics around the country. As a result of his teaching and litigation experience, he is very knowledgeable regarding the Hatch-Waxman regulatory framework and the Biologics Price Competition and Innovation Act.

Education

University of Minnesota Law School 2006
J.D.
magna cum laude


University of Wisconsin, La Crosse 2000
Biology and Chemistry, B.S.


Admissions

  • Minnesota 2006
  • California 2013
  • Supreme Court of the United States
  • U.S. Court of Appeals for the Federal Circuit

Memberships & Affiliations

​Member, American Intellectual Property Law Association, Federal Circuit Bar Association and the Federal Bar Association.

Other Distinctions

Accolades

Named to “Best Lawyers” by Best Lawyers in America (2020, 2021)

Publications

An Update On 2020 U.S. Biosimilars Regulation & Litigation,” co-authored with John Adkisson, Jenny Shmuel, and Philip Chen, Biosimilar Development (September 1, 2020).

Hatch-Waxman Success: Start the Invention Story at the Beginning,” co-authored with Chad Shear, The Recorder (August 21, 2020).

FDA Seeks to Modernize the Orange Book,” co-authored with Megan Chacon and Cheryl Wang, Fish Litigation Blog (June 22, 2020).

Generic Drug Labeling and Induced Patent Infringement,” co-authored with Brian Coggio and Karrie Wheatley, Fish Litigation Blog (June 4, 2020).

How Pandemic-Related Delays Affect Hatch-Waxman Litigants,” co-authored with Megan Chacon and Madelyn McCormick, Law360 (May 21, 2020).

Mayo at Five: Are Traditional Method of Treatment Claims in Danger Under Section 101?,” co-authored with Megan Chacon and Dalia Kothari, Fish Litigation Blog (October 9, 2017).

Mayo at Five: Eligibility of Diagnostic Method Claims,” co-authored with Megan Chacon and Dalia Kothari, Fish Litigation Blog (September 6, 2017).

Life Sciences Patent Eligibility “101”: Mayo at Five, co-authored with Megan Chacon and Dalia Kothari.

Presentations

Speaker, “Biosimilars: A 2020 Mid-Year Review,” Fish & Richardson Life Sciences Webinar Series, July 23, 2020.

Speaker, “Hatch-Waxman: Positioning Your Company For Success Against Generic Challenges,” Fish Life Sciences Webinar Series, June 16, 2020.

Lecturer, Patent Resources Group Advanced Patent Law Course, “Hatch-Waxman and Biosimilars: A Hatch-Waxman and BPCIA (Biosimilars) Immersion Course,” April 18-20, 2018.

Speaker at PatCon 8: The Annual Patent Conference, “Venue in Hatch-Waxman Cases,” March 2, 2018.

 

Experience

view all

What's trending with Geoff

Filter by
News
September 1, 2020
Fish Attorneys Author Biosimilar Development Article, "An Update On 2020 U.S. Biosimilars Regulation & Litigation"
Articles
News
News
August 25, 2020
Geoff Biegler and Chad Shear Author The Recorder Article, "Hatch-Waxman Success: Start the Invention Story at the Beginning"
Articles
News
Event
June 16th, 2020 | 1:30 pm EDT
Webinar | Hatch-Waxman: Positioning Your Company For Success Against Generic Challenges
Webinar
News Blog
July 10, 2020
Chief Judge Stark Dismisses Hatch-Waxman Case after Paragraph IV to Paragraph III Conversion
Legal Alerts
Blogs
Event
July 23rd, 2020 | 1:30 pm EDT
Webinar | Biosimilars: A 2020 Mid-Year Review
Webinar
Fish Litigation Blog
June 22, 2020
FDA Seeks to Modernize the Orange Book
Authors: Cheryl Wang, Megan A. Chacon, Geoffrey D. Biegler
Uncategorized
Fish Litigation Blog
June 4, 2020
Generic Drug Labeling and Induced Patent Infringement
Authors: Karrie Wheatley, Ph.D., Brian D. Coggio, Geoffrey D. Biegler
IP Litigation
Life Sciences
News
May 22, 2020
Fish Attorneys Author Law360 Article, "How Pandemic-Related Delays Affect Hatch-Waxman Litigants"
Articles
COVID-19
News
Event
April 15th, 2018 | 8:15 am CDT
Patent Resources Group (PRG) Spring 2018 Advanced Courses Program
Speaking Engagement
Fish Litigation Blog
October 9, 2017
Mayo at Five: Are Traditional Method of Treatment Claims in Danger Under Section 101?
Authors: Megan A. Chacon, Geoffrey D. Biegler
IP Litigation
Life Sciences
Federal Circuit
Fish Litigation Blog
September 6, 2017
Mayo at Five: Eligibility of Diagnostic Method Claims
Authors: Megan A. Chacon, Geoffrey D. Biegler
IP Litigation
Life Sciences
Federal Circuit
load more topics